Inactivation of LKB1 in mice carrying oncogenic Kras mutations leads to development of intraductal papillary mucinous neoplasm (a precursor of pancreatic cancer) (Collet et al., 2020), pancreatic cancer (Morton et al., 2010), lung adenocarcinoma (Ji et al., 2007; Murray et al., 2022; Rogers et al., 2017) and melanoma (Liu et al., 2012). The gene discussed is KRAS; the disease is familial pancreatic carcinoma.